A study conducted by MD Anderson Cancer Center, U.S., has confirmed that poziotinib can further improve the kirsten rat sarcoma virus (KRAS) inhibitory activity when administered combined with an agent inhibiting KRAS.
“Spectrum, a partner of Hanmi, announced that the results of the poziotinib combination therapy study, conducted by MD Anderson Cancer Center, during the online conference co-organized by the American Association for Cancer Research (AACR), National Cancer Institute (NCI), and European Organization for Research and Treatment of Cancer (EORTC) from last Thursday to Sunday,” Hanmi Pharmaceutical said on Tuesday.
Professor Jacqulyne Robichaux of MD Anderson Hospital said that in a preclinical model of KRAS-mutated solid cancer, a combination treatment of poziotinib and a KRASG12C inhibitor showed a synergistic effect by inhibiting EGFR, HER2, HER3, and HER4 signaling after KRASG12C inhibition.
“The data presented by MD Anderson’s team is encouraging, as it confirmed another potential of poziotinib,” Spectrum Chief Medical Officer Francois Lebel said. “It will help many patients suffering from non-small cell lung cancer and KRASG12C mutant solid cancers by benefiting them with the poziotinib-KRAS inhibitor combination therapy.”
Poziotinib is an innovative new lung cancer drug Hanmi developed and licensed out to Spectrum. It received fast-track designation from the U.S Food and Drug Administration in March.
Spectrum plans to file a marketing authorization application with the FDA at the end of this year. KBR